keyword
MENU ▼
Read by QxMD icon Read
search

Aromatase inhibitor

keyword
https://www.readbyqxmd.com/read/29244529/what-is-the-role-of-symptom-management-and-patient-reported-outcomes-in-adherence-to-aromatase-inhibitors
#1
Gabrielle Rocque
No abstract text is available yet for this article.
December 15, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29244528/phase-iii-randomized-study-of-dual-human-epidermal-growth-factor-receptor-2-her2-blockade-with-lapatinib-plus-trastuzumab-in-combination-with-an-aromatase-inhibitor-in-postmenopausal-women-with-her2-positive-hormone-receptor-positive-metastatic-breast-cancer
#2
Stephen R D Johnston, Roberto Hegg, Seock-Ah Im, In Hae Park, Olga Burdaeva, Galina Kurteva, Michael F Press, Sergei Tjulandin, Hiroji Iwata, Sergio D Simon, Sarah Kenny, Severine Sarp, Miguel A Izquierdo, Lisa S Williams, William J Gradishar
Purpose Human epidermal growth factor receptor 2 (HER2) targeting plus endocrine therapy (ET) improved clinical benefit in HER2-positive, hormone receptor (HR)-positive metastatic breast cancer (MBC) versus ET alone. Dual HER2 blockade enhances clinical benefit versus single HER2 blockade. The ALTERNATIVE study evaluated the efficacy and safety of dual HER2 blockade plus aromatase inhibitor (AI) in postmenopausal women with HER2-positive/HR-positive MBC who received prior ET and prior neo(adjuvant)/first-line trastuzumab (TRAS) plus chemotherapy...
December 15, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29243101/fractures-in-a-nationwide-population-based-cohort-of-users-of-breast-cancer-hormonal-therapy
#3
Joan M Neuner, Yushu Shi, Amanda L Kong, Sailaja Kamaraju, Elizabeth C Smith, Alicia J Smallwood, Purushottam W Laud, John A Charlson
PURPOSE: Although users of aromatase inhibitors have higher total fracture risk in some randomized trials, little is known about their risk outside of clinical trials or in older higher-risk cohorts. METHODS: In a population-based retrospective cohort study, we identified all older US Medicare D prescription drug insurance plan-enrolled women who had initial breast cancer surgery in 2006-2008 and began hormonal therapy (an aromatase inhibitor (AI) or tamoxifen) within the subsequent year...
December 15, 2017: Journal of Cancer Survivorship: Research and Practice
https://www.readbyqxmd.com/read/29234250/are-we-ready-to-use-esr1-mutations-in-clinical-practice
#4
REVIEW
Rinath Jeselsohn
The recurrent ligand-binding domain ESR1 mutations are an important mechanism of endocrine resistance in estrogen receptor-positive (ER+) metastatic breast cancer. These mutations evolve under the selective pressure of endocrine treatments and are rarely found in treatment-naïve ER+ breast cancers. Preclinical studies showed that these mutations lead to ligand-independent activity facilitating resistance to aromatase inhibitors and relative resistance to tamoxifen and fulvestrant. Retrospective analyses of ESR1 mutations in baseline plasma circulating tumor DNA from clinical trials suggest that these mutations are prognostic of poor overall survival and predictive of resistance to aromatase inhibitors in metastatic disease...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29233790/preclinical-evidence-for-combined-use-of-aromatase-inhibitors-and-nsaids-as-preventive-agents-of-tobacco-induced-lung-cancer
#5
Laura P Stabile, Mariya Farooqui, Beatriz Kanterewicz, Shira Abberbock, Brenda F Kurland, Brenda Diergaarde, Jill M Siegfried
INTRODUCTION: A hormonal role in non-small cell lung cancer (NSCLC) development is well documented. We previously showed that the aromatase inhibitor (AI) anastrozole decreased the development of tobacco carcinogen-induced lung tumors in a murine lung cancer prevention model and that aromatase and estrogen receptor (ER) were expressed in pulmonary inflammatory cells. METHODS: We utilized a tobacco carcinogen-induced lung tumor mouse model [4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK)] to determine whether an AI combined with non-steroidal anti-inflammatory drugs (NSAIDs) results in greater lung tumor prevention effects than single agent treatment...
December 9, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29233615/diet-quality-inflammation-and-quality-of-life-in-breast-cancer-survivors-a-cross-sectional-analysis-of-pilot-study-data
#6
Tonya S Orchard, Rebecca R Andridge, Lisa D Yee, Maryam B Lustberg
BACKGROUND: Modifiable lifestyle factors, such as diet quality, could reduce inflammation and improve quality of life (QOL) in breast cancer survivors, but data are inconclusive. OBJECTIVE: To determine whether diet quality, as measured by Healthy Eating Index-2010 (HEI-2010) score, is associated with inflammation, health status, or functional outcomes affecting QOL in survivors of early-stage breast cancer. DESIGN: This is a cross-sectional, secondary analysis of baseline data collected from breast cancer survivors after completion of primary therapy and before random assignment to a pilot nutritional intervention aimed at reducing side effects of aromatase inhibitor treatment...
December 9, 2017: Journal of the Academy of Nutrition and Dietetics
https://www.readbyqxmd.com/read/29231918/-systemic-treatment-of-early-breast-cancer-current-state-of-knowledge-after-the-conference-st-gallen-2017
#7
REVIEW
Tomasz Sarosiek
Breast cancer is the most commonly diagnosed malignancy in women around the globe. It is also the world's first cause of female deaths from cancer. With the introduction of screening programs in most developed countries, more and more cases of this cancer are diagnosed at local or localized stages, enabling radical treatment to be successful. At the same time, systemic treatment of early breast cancer is one of the most complex issues in clinical oncology. Because of the many prognostic factors that need to be taken into account when considering eligibility for treatment such as age, reproductive status (before or after menopause), type of cancer and severity of the disease, it is impossible to establish clear standards of conduct for many clinical situations...
November 23, 2017: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/29230660/dietary-intake-of-soy-and-cruciferous-vegetables-and-treatment-related-symptoms-in-chinese-american-and-non-hispanic-white-breast-cancer-survivors
#8
Sarah J O Nomura, Yi-Ting Hwang, Scarlett Lin Gomez, Teresa T Fung, Shu-Lan Yeh, Chiranjeev Dash, Laura Allen, Serena Philips, Leena Hilakivi-Clarke, Yun-Ling Zheng, Judy Huei-Yu Wang
PURPOSE: This project was undertaken to examine the association between dietary intake of soy or cruciferous vegetables and breast cancer treatment-related symptoms among Chinese-American (CA) and Non-Hispanic White (NHW) breast cancer survivors. METHODS: This cross-sectional study included 192 CA and 173 NHW female breast cancer survivors (stages 0-III, diagnosed between 2006 and 2012) recruited from two California cancer registries, who had completed primary treatment...
December 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29230302/letrozole-induced-hepatitis-with-autoimmune-features-a-rare-adverse-drug-reaction-with-review-of-the-relevant-literature
#9
Bharatsinh Gharia, Karan Seegobin, Satish Maharaj, Noor Marji, Amie Deutch, Lara Zuberi
While aromatase inhibitors (AIs) have been known to cause minor elevations in liver enzymes, severe hepatotoxicity is rare. To the best of our knowledge, this is the first reported case of Letrozole-induced hepatitis with autoimmune features. A 70-year-old female with estrogen positive, invasive ductal carcinoma of the breast, presented with jaundice 3 months after starting letrozole. Hepatic transaminases were markedly elevated and her ANA and anti-smooth muscle antibody was positive. Liver biopsy featured drug-induced hepatitis...
November 2017: Oxford Medical Case Reports
https://www.readbyqxmd.com/read/29230126/endocrine-therapy-for-early-breast-cancer-updated-review
#10
REVIEW
Alexander Tremont, Jonathan Lu, John T Cole
Background: Although breast cancer is still the second most common cause of cancer-related deaths, breast cancer mortality has been declining because of advances in the use of adjuvant therapies. Methods: We summarize clinical trials involving endocrine therapies used to treat early breast cancer and discuss their inception and recent advances. Results: Endocrine therapies such as tamoxifen have revolutionized the treatment of breast cancer, resulting in significant decreases in cancer-related mortality...
2017: Ochsner Journal
https://www.readbyqxmd.com/read/29229849/obligatory-role-of-hypothalamic-neuroestradiol-during-the-estrogen-induced-lh-surge-in-female-ovariectomized-rhesus-monkeys
#11
Brian P Kenealy, Kim L Keen, James P Garcia, Lucille K Kohlenberg, Ei Terasawa
Negative and positive feedback effects of ovarian 17β-estradiol (E2) regulating release of gonadotropin releasing hormone (GnRH) and luteinizing hormone (LH) are pivotal events in female reproductive function. While ovarian feedback on hypothalamo-pituitary function is a well-established concept, the present study shows that neuroestradiol, locally synthesized in the hypothalamus, is a part of estrogen's positive feedback loop. In experiment 1, E2 benzoate-induced LH surges in ovariectomized female monkeys were severely attenuated by systemic administration of the aromatase inhibitor, letrozole...
December 11, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/29229551/modulation-of-reactive-oxygen-species-via-erk-and-stat3-dependent-signalling-are-involved-in-the-response-of-mesothelioma-cells-to-exemestane
#12
Barbara Nuvoli, Emanuela Camera, Arianna Mastrofrancesco, Stefania Briganti, Rossella Galati
Pleural mesothelioma is a deadly form of cancer. The prognosis is extremely poor due to the limited treatment modalities. Uptake of asbestos fibres, the leading cause of mesothelioma, lead to the accumulation of reactive-oxygen-species (ROS). Interestingly, increasing ROS production by using ROS-generating drugs may offer a strategy to selectively trigger cell death. Exemestane, an aromatase inhibitor, has previously shown anti-tumor properties in mesothelioma preclinical models suggesting a role of G protein-coupled receptor 30 (GPR30) in the drug response...
December 8, 2017: Free Radical Biology & Medicine
https://www.readbyqxmd.com/read/29223989/geographic-variation-of-adjuvant-breast-cancer-therapy-initiation-in-the-united-states-lessons-from-medicare-part-d
#13
John A Charlson, Emily L McGinley, Ann B Nattinger, Joan M Neuner, Liliana E Pezzin
Background: Drug utilization under Medicare Part D varies significantly by geographic region. This study examined the extent to which geographic variation in Part D plan characteristics contributes to the variation in choice of initial endocrine therapy agent among women with incident breast cancer. Methods: Two-stage multivariate regression analyses were applied to the 16,541 women identified from Medicare claims as having incident breast cancer in 2006-2007. The first stage determined the effect of state of residence on the probability of having an aromatase inhibitor (AI), as opposed to tamoxifen, as initial endocrine therapy...
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29214214/molecular-changes-in-premenopausal-oestrogen-receptor-positive-primary-breast-cancer-in-vietnamese-women-after-oophorectomy
#14
Ben P Haynes, Ophira Ginsburg, Qiong Gao, Elizabeth Folkerd, Maria Afentakis, Le Hong Quang, Pham Thi Han, Pham Hong Khoa, Nguyen Van Dinh, Ta Van To, Mark Clemons, Ian E Smith, Mitch Dowsett
For premenopausal women with primary ER + breast cancer, oophorectomy (OvX) is an evidence-based cost-effective option and is standard treatment in many countries. However, there is virtually no data describing the effects of OvX on breast tumour biology. We therefore, characterised the endocrine and genome-wide transcriptional impact of OvX in 56 premenopausal women with ER + breast cancer for 2 weeks prior to mastectomy. Plasma estradiol concentrations decreased from 406 ± 41 to 20.7 ± 2...
2017: NPJ Breast Cancer
https://www.readbyqxmd.com/read/29212872/parotid-gland-an-unusual-site-of-breast-cancer-metastasis
#15
Thomas Rawet, Apurna Jegannathen, Soni Soumian
Parotid gland metastases from breast cancer are an extremely rare and unusual event with a limited number of cases recorded in the literature. A 71-year-old woman with a history of ductal adenocarcinoma of the left breast presented to the maxillofacial clinic with an asymptomatic swelling of the left parotid gland. The presentation occurred 21 years after she underwent treatment for recurrent breast cancer. Investigations led to the diagnosis of a breast cancer metastasis which was oestrogen receptor and progesterone receptor positive and negative...
December 5, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/29212847/attempted-replication-of-snps-in-rankl-and-opg-with-musculoskeletal-adverse-events-during-aromatase-inhibitor-treatment-for-breast-cancer
#16
Jacqueline M Dempsey, Jingyue Xi, N Lynn Henry, James M Rae, Daniel L Hertz
Aromatase inhibitor (AI) therapy is highly efficacious in the treatment of estrogen receptor-positive breast cancer, however in a subset of patients AI use is discontinued due to drug-induced musculoskeletal adverse events (MS-AE). Several studies have investigated the role of germline single nucleotide polymorphisms on patients' risk of MS-AE's, however no associations have yet to be validated for translation into clinical practice. This study attempted to replicate SNPs in RANKL (rs7984870) and OPG (rs2073618) on the risk of AI-induced MS-AEs, and screen for secondary associations with MS-AE related treatment discontinuation and serum and urine markers of bone health...
December 6, 2017: Physiological Genomics
https://www.readbyqxmd.com/read/29205077/forty-years-of-landmark-trials-undertaken-by-the-danish-breast-cancer-cooperative-group-dbcg-nationwide-or-in-international-collaboration
#17
Bent Ejlertsen, Birgitte Vrou Offersen, Jens Overgaard, Peer Christiansen, Maj-Britt Jensen, Niels Kroman, Ann Søgaard Knoop, Henning Mouridsen
BACKGROUND: Over the past 40 years the Danish Breast Cancer Cooperative Group (DBCG) has made significant contributions to improve outcome and to make treatment of patients with early breast cancer more tolerable through nationwide and international trials evaluating loco-regional and systemic treatments. These trials have been instrumental to establish standards for the treatment of early breast cancer. METHODS: The DBCG 82 trials had a global impact by documenting that the significant gain in loco-regional recurrence from postmastectomy radiation added to systemic therapy was associated with a reduction in distant recurrence and mortality in high-risk pre- and postmenopausal patients...
December 5, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29202611/aurora-kinase-a-as-a-possible-marker-for-endocrine-resistance-in-early-estrogen-receptor-positive-breast-cancer
#18
Anne E Lykkesfeldt, Benedikte R Iversen, Maj-Britt Jensen, Bent Ejlertsen, Anita Giobbie-Hurder, Birgit E Reiter, Tove Kirkegaard, Birgitte B Rasmussen
BACKGROUND: Cell culture studies have disclosed that the mitotic Aurora kinase A is causally involved in both tamoxifen and aromatase inhibitor resistant cell growth and thus may be a potential new marker for endocrine resistance in the clinical setting. MATERIAL AND METHODS: Archival tumor tissue was available from 1323 Danish patients with estrogen receptor (ER) positive primary breast cancer, who participated in the Breast International Group (BIG) 1-98 trial, comparing treatment with tamoxifen and letrozole and both in a sequence...
December 4, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29202405/potent-aromatase-inhibitors-and-molecular-mechanism-of-inhibitory-action
#19
Hongjun Kang, Xingqing Xiao, Chao Huang, Yan Yuan, Dongyan Tang, Xiaochang Dai, Xianghui Zeng
Estrogen is a significant factor in the maintenance and progression of hormone-dependent breast cancer. As well known, aromatase mediates the production of estrogen. Thus, inhibition of aromatase with chemical molecules has been considered to be an effective treatment for estrogen receptor-positive (ER+) breast cancer. In this work, we designed and synthesized a series of novel non-steroidal molecules containing 2-phenylindole scaffold and moiety of either imidazole or 1,2,4-triazole to enhance their binding capacity with the aromatase...
November 22, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29194370/alternative-oral-agents-in-prophylaxis-and-therapy-of-uterine-fibroids-an-up-to-date-review
#20
REVIEW
Michał Ciebiera, Krzysztof Łukaszuk, Błażej Męczekalski, Magdalena Ciebiera, Cezary Wojtyła, Aneta Słabuszewska-Jóźwiak, Grzegorz Jakiel
Uterine fibroids (UFs) are the most common tumors of the female genital tract. The effect of UFs on the quality of life and the overall cost of treatment are significant issues worldwide. Tumor size and location are the two specific factors which influence the occurrence of symptoms, the need for, and method of, treatment (some tumors require surgery while some can be treated with selected drugs). Primary prevention and treatment of early UF disease are worthy goals that might have a great impact on health care systems...
December 1, 2017: International Journal of Molecular Sciences
keyword
keyword
4026
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"